Brief: Regeneron and Sillajen report immuno-oncology clinical study agreement

SillaJen

08/05/2017 13:30

May 8 (Reuters) - Sillajen Inc  215600.KQ : 
    * Regeneron and Sillajen announce immuno-oncology clinical 
study agreement for combination treatment in kidney cancer 
    * Regeneron - phase 1b clinical trial will evaluate 
combination of regeneron's pd-1 inhibitor regn2810 and 
Sillajen's pexa-vec, an oncolytic virus 
    * Regeneron Pharmaceuticals - under terms of agreement, 
trial will be solely conducted, funded by sillajen based upon 
mutually developed study design 
    * Regeneron Pharmaceuticals Inc - co, Sanofi is developing 
regn2810 both alone and in combination with other therapies for 
treatment of various cancers 
    * Regeneron Pharmaceuticals- open-label trial for phase 1b 
dose-escalation study is expected to begin later this year 
    * Regeneron Pharmaceuticals- phase 1b dose-escalation study 
will initially open in Korea, with expansion to sites in U.S. 
 
Source text for Eikon:  ID:nPn9LQZ29a  
Further company coverage:  215600.KQ  
 
 ((bangalore.newsroom@thomsonreuters.com;))